The agent gained a priority review designation for use in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy, based on ...

Cancer drug Kyprolis failed to improve overall survival in a Phase-III trial involving patients with relapsed and advanced refractory multiple myeloma, said Amgen and its subsidiary Onyx yesterday.

Kyprolis doubled progression-free survival versus Velcade in patients with relapsed multiple myeloma in the phase 3 ENDEAVOR trial. Kyprolis (carfilzomib) doubled progression-free survival (PFS) ...

Approval Based on Data From Pivotal Phase 3 ASPIRE Trial Which Demonstrated Patients Treated With Kyprolis in Combination Lived Nearly Nine Months Longer Without Disease Progression Compared to Common ...

After years of slow growth, Amgen’s Kyprolis finally looks poised to break the blockbuster barrier in 2019, and new data in tandem with the multiple myeloma field’s hottest drug could help boost it ...

Kyprlois is currently approval for use in multiple myeloma patients who have progressed on 2 prior therapies. Amgen and its subsidiary Onyx Pharmaceuticals have submitted filings for their multiple ...

Amgen has submitted a supplemental New Drug Application to the FDA to expand the prescribing information of carfilzomib (Kyprolis) to include a once-weekly dosing option in combination with ...

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean ...

(Reuters) - Amgen Inc's Kyprolis helped patients with relapsed multiple myeloma live twice as long before their blood cancer worsened compared to a regimen containing rival drug Velcade, according to ...

SAN DIEGO--(BUSINESS WIRE)-- Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces that a major Captisol customer Amgen (NASDAQ: AMGN) has received U.S. Food and Drug Administration (FDA) ...

Monday - Friday, 2:00 - 3:00 PM ET Biopharmaceutical firm Amgen potentially may have scored a win with its new cancer drug, Kyprolis. Kyprolis, a proteasome inhibitor used in the treatment of a type ...

THOUSAND OAKS, Calif., May 5, 2020 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. District Court in Delaware issued a decision upholding the validity of patent claims from three ...